Philippe Moris

4.2k citations
54 papers · 3.0k · 1 hit paper · h-index 31

Impact in

Papers in

  • Epidemiology 28
    • Influenza Virus Research Studies 11
    • Hepatitis B Virus Studies 6
    • Cervical Cancer and HPV Research 5
    • Respiratory viral infections research 5
  • Immunology 15
    • Immunotherapy and Immune Responses 8
Co-authors
Opokua Ofori‐Anyinam (15 shared papers)Emmanuel Hanon (4 shared papers)Geert Leroux‐Roels (10 shared papers)Joe Cohen (12 shared papers)Frédéric Clément (6 shared papers)Erik Jongert (11 shared papers)Marie‐Ange Demoitié (9 shared papers)Francis Dessy (3 shared papers)
Journals
Vaccine (11 papers)Human Vaccines & Immunotherapeutics (7 papers)Tuberculosis (3 papers)PLoS ONE (3 papers)Human Vaccines (2 papers)
Partner nations
BelgiumUnited StatesUnited Kingdom

In The Last Decade

Philippe Moris

53 papers receiving 2.8k citations

Philippe Moris's Hit Papers

Randomized, Double‐Blind, Phase 2a Trial of Falciparum Malaria Vaccines RTS,S/AS01B and RTS,S/AS02A in Malaria‐Naive Adults: Safety, Efficacy, and Immunologic Associates of Protection 2009 · 387 citations
3870+5+11Years since publication100200300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

  • it has ≥500 total citations;
  • it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
  • it reaches the top citation threshold in at least one of its specific research topics.
  1. 2009 The Journal of Infectious Diseases

Peers

Philippe Moris
Comparison fields: 5 of 95
  • Immunology 1.3k
  • Infectious Diseases 875
  • Epidemiology 1.2k
  • Virology 164
  • Microbiology 131
Replace Nigel Temperton with:
Nigel Temperton United Kingdom
Frédéric Clément Belgium
Susan L. Baldwin United States
Benjamin Wizel United States
Tamara Berthoud United Kingdom
Opokua Ofori‐Anyinam Belgium
Raffael Nachbagauer United States
Anja Seubert Italy
Erik B. Lindblad Denmark
Donata Medaglini Italy
Philippe Moris relative to Nigel Temperton United Kingdom Nigel Temperton's profile →
Citations per field
00.5×1.5×2.0×
Nigel Temperton · 1×
Citations per year

Countries citing papers authored by Philippe Moris

Since Specialization
Citations

This map shows the geographic impact of Philippe Moris's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philippe Moris with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philippe Moris more than expected).

Fields of papers citing papers by Philippe Moris

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philippe Moris. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philippe Moris. The network helps show where Philippe Moris may publish in the future.

Co-authors

The 25 scholars most cited alongside Philippe Moris, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Philippe Moris Line = papers co-authored together Philippe Moris links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 54 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only
Vaccine ·Sandro Giannini, Emmanuel Hanon, Philippe Moris, Maxime Vanmechelen, S. Morel, Francis Dessy, Marc Fourneau, Brigitte Colau, Jon B. Suzich, G LOSONKSY
2006408
2
Randomized, Double‐Blind, Phase 2a Trial of Falciparum Malaria Vaccines RTS,S/AS01B and RTS,S/AS02A in Malaria‐Naive Adults: Safety, Efficacy, and Immunologic Associates of Protection
The Journal of Infectious Diseases ·Kent E. Kester, James F. Cummings, Opokua Ofori‐Anyinam, Christian F. Ockenhouse, Urszula Krzych, Philippe Moris, Robert Schwenk, Robin A. Nielsen, Zufan Debebe, Evgeny Pinelis, Laure Juompan, Jack Williams, Megan Dowler, V. Ann Stewart, Robert A. Wirtz, Marie‐Claude Dubois, Marc Lievens, Joe Cohen, W. Ripley Ballou, D. Gray Heppner, (unknown)
Hit paper breakdown →		2009387
3
Vaccine Adjuvant Systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers
Vaccine ·Pierre Vandepapelière, Yves Horsmans, Philippe Moris, Marcelle Van Mechelen, Michel Janssens, Marguerite Koutsoukos, Pascale Van Belle, Frédéric Clément, Emmanuel Hanon, Martine Wettendorff, Nathalie Garçon, Geert Leroux‐Roels
2008186
4
H5N1 Influenza Vaccine Formulated with AS03A Induces Strong Cross-Reactive and Polyfunctional CD4 T-Cell Responses
Journal of Clinical Immunology ·Philippe Moris, Robbert van der Most, Isabel Leroux‐Roels, Frédéric Clément, Mamadou Dramé, Emmanuel Hanon, Geert Leroux‐Roels, Marcelle Van Mechelen
2010134
5
Improved CD4+ T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72/AS01 as compared to the M72/AS02 and Mtb72F/AS02 tuberculosis candidate vaccine formulations: A randomized trial
Vaccine ·Isabel Leroux‐Roels, Sheron Forgus, Fien De Boever, Frédéric Clément, Marie‐Ange Demoitié, Pascal Mettens, Philippe Moris, Edouard Ledent, Geert Leroux‐Roels, Opokua Ofori‐Anyinam
2012130
6
Safety and immunogenicity of candidate vaccine M72/AS01E in adolescents in a TB endemic setting
Vaccine ·Adam Penn‐Nicholson, Hennie Geldenhuys, Wivine Burny, Robbert van der Most, Cheryl L. Day, Erik Jongert, Philippe Moris, Mark Hatherill, Opokua Ofori‐Anyinam, Willem A. Hanekom, Anne Bollaerts, Marie‐Ange Demoitié, Angelique Kany Kany Luabeya, Evi De Ruymaeker, Michèle Tameris, Didier Lapierre, Thomas J. Scriba
2015104
7
The candidate tuberculosis vaccine Mtb72F/AS02A: Tolerability and immunogenicity in humans
Human Vaccines ·Kenneth Von Eschen, Royce A. Morrison, Madeleine Braun, Opokua Ofori‐Anyinam, Els De Kock, Priya Pavithran, Marguerite Koutsoukos, Philippe Moris, Daniel Cain, Marie‐Claude Dubois, Joe Cohen, W. Ripley Ballou
200993
8
Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18–45 years
Human Vaccines ·Mark H. Einstein, Mira Baron, Myron J. Levin, Archana Chatterjee, Bradley Fox, Sofia Scholar, Jeffrey B. Rosen, Nahida Chakhtoura, Marie Lebacq, Robbert van der Most, Philippe Moris, Sandra L. Giannini, Anne Schuind, Sanjoy Datta, Dominique Descamps
201192
9
Circumsporozoite-Specific T Cell Responses in Children Vaccinated with RTS,S/AS01E and Protection against P falciparum Clinical Malaria
PLoS ONE ·Ally Olotu, Philippe Moris, Jedidah Mwacharo, Johan Vekemans, Domtila Kimani, Michel Janssens, Oscar Kai, Erik Jongert, Marc Lievens, Amanda Leach, Tonya Villafana, Barbara Savarese, Kevin Marsh, Joe Cohen, Philip Bejon
201176
10
Antigen-Specific IL-2 Secretion Correlates with NK Cell Responses after Immunization of Tanzanian Children with the RTS,S/AS01 Malaria Vaccine
The Journal of Immunology ·Amir Horowitz, Julius Clemence R. Hafalla, Elizabeth C. King, John Lusingu, Denise Dekker, Amanda Leach, Philippe Moris, Joe Cohen, Johan Vekemans, Tonya Villafana, Patrick H. Corran, Philip Bejon, Chris J. Drakeley, Lorenz von Seidlein, Eleanor M. Riley
201274
11
Protective Immunity Induced with the RTS,S/AS Vaccine Is Associated with IL-2 and TNF-α Producing Effector and Central Memory CD4+ T Cells
PLoS ONE ·Joanne M. Lumsden, Robert Schwenk, Lisa Rein, Philippe Moris, Michel Janssens, Opokua Ofori‐Anyinam, Joe Cohen, Kent E. Kester, D. Gray Heppner, Urszula Krzych
201173
12
A Randomized, Controlled Dose-Finding Phase II Study of the M72/AS01 Candidate Tuberculosis Vaccine in Healthy PPD-Positive Adults
Journal of Clinical Immunology ·Jaime Montoya, Juan Antonio Solon, Soledad Rosanna C. Cunanan, Luz P. Acosta, Anne Bollaerts, Philippe Moris, Michel Janssens, Erik Jongert, Marie‐Ange Demoitié, Pascal Mettens, Salvacion Gatchalian, Carlota Vinals, Joe Cohen, Opokua Ofori‐Anyinam
201371
13
Immunogenicity and Safety of H5N1 A/Vietnam/1194/2004 (Clade 1) AS03-Adjuvanted Prepandemic Candidate Influenza Vaccines in Children Aged 3 to 9 Years
The Pediatric Infectious Disease Journal ·Javier Díez‐Domingo, María Garcés‐Sánchez, José-Marı́a Baldó, María Victoria Planelles, Isabel Ubeda, Angels Jubert, Josep Marés, Philippe Moris, Pilar Garcı́a-Corbeira, Mamadou Dramé, Paul Gillard
201067
14
Safety and immunogenicity of the M72/AS01 E candidate tuberculosis vaccine in adults with tuberculosis: A phase II randomised study
Tuberculosis ·Paul Gillard, Pan‐Chyr Yang, Manfred Danilovitš, Wei‐Juin Su, Shih-Lung Cheng, Lea Pehme, Anne Bollaerts, Erik Jongert, Philippe Moris, Opokua Ofori‐Anyinam, Marie‐Ange Demoitié, Marcela Castro
201661
15
Safety and immunogenicity of an investigational 4-component Staphylococcus aureus vaccine with or without AS03 B adjuvant: Results of a randomized phase I trial
Human Vaccines & Immunotherapeutics ·Jack Lévy, Laurent Licini, Edwige Haelterman, Philippe Moris, Pascal Lestrate, Silvia Damaso, Pascale Van Belle, Dominique Boutriau
201557
16
Adjuvant system AS02V enhances humoral and cellular immune responses to pneumococcal protein PhtD vaccine in healthy young and older adults: Randomised, controlled trials
Vaccine ·Isabel Leroux‐Roels, Jeanne‐Marie Devaster, Geert Leroux‐Roels, Vincent Verlant, Isabelle Henckaerts, Philippe Moris, Philippe Hermand, Pascale Van Belle, Jan Poolman, Pierre Vandepapelière, Yves Horsmans
201356
17
Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18–45 years: Follow-up through Month 48 in a Phase III randomized study
Human Vaccines & Immunotherapeutics ·Mark H. Einstein, Myron J. Levin, Archana Chatterjee, Nahida Chakhtoura, Péter Takács, Grégory Catteau, Francis Dessy, Philippe Moris, Lan Lin, Frank Struyf, Gary Dubin
201453
18
Evaluation of the immune response to RTS,S/AS01 and RTS,S/AS02 adjuvanted vaccines
Human Vaccines & Immunotherapeutics ·Geert Leroux‐Roels, Isabel Leroux‐Roels, Frédéric Clément, Opokua Ofori‐Anyinam, Marc Lievens, Erik Jongert, Philippe Moris, W. Ripley Ballou, Joe Cohen
201450
19
Safety and immunogenicity of the M72/AS01 candidate tuberculosis vaccine when given as a booster to BCG in Gambian infants: An open-label randomized controlled trial
Tuberculosis ·Olubukola T. Idoko, Olumuyiwa Owolabi, Patrick K. Owiafe, Philippe Moris, Aderonke Odutola, Anne Bollaerts, Ezra Olatunde Ogundare, Erik Jongert, Marie‐Ange Demoitié, Opokua Ofori‐Anyinam, Martin O. C. Ota
201449
20
First-in-Human Randomized Study to Assess the Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus (RSV) Vaccine Based on Chimpanzee-Adenovirus-155 Viral Vector–Expressing RSV Fusion, Nucleocapsid, and Antitermination Viral Proteins in Healthy Adults
Clinical Infectious Diseases ·Paola Cicconi, Claire Jones, Esha Sarkar, Laura Silva-Reyes, Paul Klenerman, Catherine de Lara, Claire Hutchings, Philippe Moris, Michel Janssens, Laurence Fissette, Marta Picciolato, Amanda Leach, A González‐López, Ilse Dieussaert, Matthew D. Snape
201946

About Philippe Moris

Philippe Moris is a scholar working on Epidemiology, Immunology, Infectious Diseases, Public Health, Environmental and Occupational Health and Molecular Biology, having authored 54 papers that have together received 3.0k indexed citations. Recurring topics across this work include Malaria Research and Control (12 papers), Influenza Virus Research Studies (11 papers), Tuberculosis Research and Epidemiology (8 papers), Immunotherapy and Immune Responses (8 papers), Mosquito-borne diseases and control (7 papers), Hepatitis B Virus Studies (6 papers), Cervical Cancer and HPV Research (5 papers) and Respiratory viral infections research (5 papers). The work is most often cited by research in Immunology (1.3k citations), Infectious Diseases (875 citations), Epidemiology (1.2k citations), Virology (164 citations) and Microbiology (131 citations). Philippe Moris has collaborated with scholars based in Belgium, United States and United Kingdom. Frequent co-authors include Opokua Ofori‐Anyinam, Emmanuel Hanon, Geert Leroux‐Roels, Joe Cohen, Frédéric Clément, Erik Jongert, Marie‐Ange Demoitié, Francis Dessy, Isabel Leroux‐Roels and Robbert van der Most. Their work appears in journals such as Vaccine, Human Vaccines & Immunotherapeutics, Tuberculosis, PLoS ONE and Human Vaccines.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nigel TempertonBreakdown of academic impact, for papers by Frédéric ClémentBreakdown of academic impact, for papers by Susan L. BaldwinBreakdown of academic impact, for papers by Benjamin WizelBreakdown of academic impact, for papers by Tamara BerthoudBreakdown of academic impact, for papers by Opokua Ofori‐AnyinamBreakdown of academic impact, for papers by Raffael NachbagauerBreakdown of academic impact, for papers by Anja SeubertBreakdown of academic impact, for papers by Erik B. LindbladBreakdown of academic impact, for papers by Donata Medaglini